UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?

Cancer and metastasis reviews, 2020-09, Vol.39 (3), p.969-987

2020

Volltextzugriff (PDF)

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

Cancer research (Chicago, Ill.), 2009-07, Vol.69 (14), p.5627-5629

2009

Volltextzugriff (PDF)

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing

PloS one, 2017-08, Vol.12 (8), p.e0183390-e0183390

2017

Volltextzugriff (PDF)

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Nature communications, 2019-05, Vol.10 (1), p.2087-12, Article 2087

2019

Volltextzugriff (PDF)

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors

mAbs, 2023-12, Vol.15 (1), p.2208697

2023

Volltextzugriff (PDF)

Intratumoral injection and retention hold promise to improve cytokine therapies for cancer

Frontiers in oncology, 2024-08, Vol.14, p.1456658

2024

Volltextzugriff (PDF)

On the abundance of EpCAM on cancer stem cells

Nature reviews. Cancer, 2009-02, Vol.9 (2), p.143-143

2009

Volltextzugriff (PDF)

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors

Oncoimmunology, 2023-12, Vol.12 (1), p.2182058-2182058

2023

Volltextzugriff (PDF)

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

Cancer research (Chicago, Ill.), 2009-06, Vol.69 (12), p.4941-4944

2009

Volltextzugriff (PDF)

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

Proceedings of the National Academy of Sciences - PNAS, 2010-07, Vol.107 (28), p.12605-12610

2010

Volltextzugriff (PDF)

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110

PloS one, 2015-10, Vol.10 (10), p.e0141669-e0141669

2015

Volltextzugriff (PDF)

T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities

Current opinion in oncology, 2022-09, Vol.34 (5), p.552-558

2022

Volltextzugriff (PDF)

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells

PloS one, 2010-10, Vol.5 (10), p.e13474-e13474

2010

Volltextzugriff (PDF)

Blinatumomab: a historical perspective

Pharmacology & therapeutics (Oxford), 2012-12, Vol.136 (3), p.334-342

2012

Volltextzugriff (PDF)

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

Experimental cell research, 2011-05, Vol.317 (9), p.1255-1260

2011

Volltextzugriff (PDF)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e003882

2022

Volltextzugriff (PDF)

Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer

Current pharmaceutical biotechnology, 2012-06, Vol.13 (8), p.1399-1408

2012

Volltextzugriff (PDF)

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

Cancer cell international, 2010-11, Vol.10 (1), p.44-44, Article 44

2010

Volltextzugriff (PDF)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Experimental hematology & oncology, 2017-05, Vol.6 (1), p.14-14, Article 14

2017

Volltextzugriff (PDF)

Targeting T cells to tumor cells using bispecific antibodies

Current opinion in chemical biology, 2013-06, Vol.17 (3), p.385-392

2013

Volltextzugriff (PDF)

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

Journal for immunotherapy of cancer, 2023-08, Vol.11 (8), p.e007398

2023

Volltextzugriff (PDF)

CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease

The Journal of experimental medicine, 2024-05, Vol.221 (5)

2024

Volltextzugriff (PDF)

Nuclear signalling by tumour-associated antigen EpCAM

Nature cell biology, 2009-02, Vol.11 (2), p.162-171

2009

Volltextzugriff (PDF)

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1104-1111

2016

Volltextzugriff (PDF)

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

Clinical cancer research, 2012-01, Vol.18 (2), p.465-474

2012

Volltextzugriff (PDF)

1 – 25 von 334

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(309)
Mit Volltextzugriff
(302)

Publikationsform

Sprache

Englisch
(334)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(214)
Life Sciences & Biomedicine
(180)
Humans
(164)
Animals
(105)
Biological And Medical Sciences
(68)
Biochemistry & Molecular Biology
(65)
Mice
(56)
Immunology
(55)
Oncology
(52)
Nf-Kappa B - Metabolism
(48)
Molecular Sequence Data
(47)
T-Lymphocytes - Immunology
(41)
Base Sequence
(39)
Medical Sciences
(38)
Cell Biology
(35)
Immunotherapy
(34)
Female
(31)
Cd3 Complex - Immunology
(30)
Fundamental And Applied Biological Sciences. Psychology
(30)
Antibodies, Bispecific - Immunology
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors

Intratumoral injection and retention hold promise to improve cytokine therapies for cancer

On the abundance of EpCAM on cancer stem cells

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110

T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells

Blinatumomab: a historical perspective

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Targeting T cells to tumor cells using bispecific antibodies

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease

Nuclear signalling by tumour-associated antigen EpCAM

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

Suchergebnisse filtern